お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
950721

COVID-19関連製薬業界の世界市場:ワクチン、治療薬、研究開発機器、消耗品、製造工場、2020年~2024年

COVID-19 Pharma Industry (COVID-19 Vaccines, COVID-19 Drugs, R&D Equipment & Consumables and COVID-19 Vaccines Manufacturing Plants) Market 2020-2024: Worth More Than* $300 Billion/Annum, 5 Submarkets, 2 Scenarios

出版日: | 発行: Homeland Security Research Corporation (HSRC) | ページ情報: 英文 420 Pages; 215 Tables & Figures | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
COVID-19関連製薬業界の世界市場:ワクチン、治療薬、研究開発機器、消耗品、製造工場、2020年~2024年
出版日: 2020年07月24日
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 420 Pages; 215 Tables & Figures
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

新型コロナウイルス感染症(COVID-19)のパンデミックが続くなか、2020年6月26日の時点で270を超える治療薬とワクチンの開発が進められています(このうちの約85%が前臨床段階)。

医薬品研究のアプローチとしては、体内で繁殖するウイルスの能力に直接影響を与える抗ウイルス薬、免疫系が過剰反応し心臓や腎臓などに害を及ぼすような場面で免疫系を落ち着かせる薬、ウイルスを攻撃する抗体の3つがあります。

ワクチン開発には、通常8年から12年の歳月が必要であり、専門家の多くは、18ヶ月でワクチンを開発するのは非常に厳しいスケジュールであると指摘しています。楽観的なシナリオとして、2021年7月までに数千万人分のワクチンが準備できるとの見方もありますが、その一方で2025年まで集団予防接種はできないという見方もあります。

当レポートは、世界のCOVID-19ワクチンや治療薬、製造プラント、研究開発機器、消耗品などの市場を調査したもので、成長促進要因と阻害要因、ビジネスチャンス、SWOT分析、競合分析、事業環境などの情報を提供しています。

A. 当レポートが対応している主な疑問点

  • COVID-19関連製薬業界(ワクチン、治療薬、研究開発機器、消耗品、製造工場)の市場規模はどのくらいか。2020年から2024年までに予測されるトレンドはどのようなものか。
  • 最も魅力的なビジネスチャンスは何か。
  • 顧客にソリューションやサービスの購入を促す要因は何か。
  • 市場のトレンドはどのようなものか。
  • 2020年から2024年までの5つサブマーケットの規模どのくらいか。
  • 市場への浸透と成長を促進するうえでの課題は何か。

B. 市場分析のためのフレームワーク

  • 1.市場の成長促進要因と阻害要因
  • 2.ビジネスチャンス
  • 3. SWOT分析
  • 4.各種の製品とサービスの競合分析
    • 1.参入障壁
    • 2.サプライヤーの力
    • 3.バイヤーの力
    • 4.代替製品の障壁
  • 5.事業環境
  • 6.サブマーケットの予測
目次

The report includes the analysis of the following 5 COVID-19 related pharma sub-markets:

  • 1. COVID-19 Vaccines
  • 2. COVID-19 Therapeutic Drugs
  • 3. Other COVID-19 Pharma Industry Products
  • 4. COVID-19 Vaccine Manufacturing Plants
  • 5. R&D Equipment & Consumables

The Coronavirus pandemic has led to an acute deficiencies of COVID-19 therapeutic drugs, COVID-19 vaccines, other COVID-19 pharma products, and vaccines manufacturing lines. Once medical regulating bodies certify the vaccines and therapeutic drugs to be safe and effective, legislators, regulation agencies and the global healthcare community will be faced with ration and allocation dilemmas when distributing these lifesaving medicines.

COVID-19 Drugs

The global pharma industry and medical research bodies are investing in and concentrating resources on discovering and developing COVID-19 drugs and vaccines. There are more than 270 (approximately 85% in the pre-clinical phase) drugs and vaccines under development as of June 26, 2020.

There are more than 140 distinct therapeutic drugs being researched around the world. The majority of current drugs that are being trialed against the virus. WHO has introduced the Solidarity trial aimed at assessing the most promising treatments

There are three main COVID-19 drug investigation approaches:

  • Antiviral drugs that directly affect the virus's ability to flourish in the body
  • Medications that can calm down the immune system when the immune system overreacts, causing cardiac, renal or other harm to the body
  • Antibodies, either from survivors' blood or lab-made antibodies, which attack the virus

COVID-19 Vaccines

Vaccine creators are rushing to develop COVID-19 vaccines and have enhanced ten candidates entered into clinical trials.

Vaccine development is typically a long game. For example, the FDA approved a first vaccine against Ebola virus last year, 43 years after the Ebola virus was revealed. Vaccine developers have made little headway with HIV or pulmonary syncytial virus, in spite of massive investments. It takes 8-12 years on average, to develop a vaccine. With the COVID-19 crisis looming, everyone is hoping that this time will be different.

Most experts argue that 18 months for a first vaccine is an extremely hard-hitting schedule, some believe that tens of millions of COVID-19 vaccines doses might be prepared for distribution by July 2021. Nobody knows, if and when a safe and effective vaccine will save the day.

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

  • 1. Optimistic scenario - assumes (among other things) that mass vaccination will commence by July 2021
  • 2. Conservative scenario - assumes (among other things) that no mass vaccination will be available until 2025

Why Buy this COVID-19 Pharma Industry (COVID-19 Vaccines, COVID-19 Drugs, R&D Equipment & Consumables and COVID-19 Vaccines Manufacturing Plants) Market - 2020-2024 Report?

A. Questions answered in this report include:

  • What is the COVID-19 Pharma Industry (COVID-19 Vaccines, COVID-19 Drugs, R&D Equipment & Consumables and COVID-19 Vaccines Manufacturing Plants) Market size and what are the forecast trends during 2020-2024?
  • What are the most attractive business opportunities?
  • What drives the customers to purchase solutions and services?
  • What are the COVID-19 Pharma Industry (COVID-19 Vaccines, COVID-19 Drugs, R&D Equipment & Consumables and COVID-19 Vaccines Manufacturing Plants) Market trends?
  • What is the 5 sub-markets size over the 2020-2024 period?
  • What are the challenges to market penetration & growth?

B. Detailed market analysis frameworks for each of the market sectors are provided, including:

  • 1. Market drivers & inhibitors
  • 2. Business opportunities
  • 3. SWOT analysis
  • 4. Competitive analysis for each of the products and services that covers:
    • 1. Barriers to Entry
    • 2. Supplier Power
    • 3. Buyer Power
    • 4. Barriers to Substitution.
  • 5. Business environment
  • 6. The 2020-2024 market segmented into 5 submarkets
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.